Daiichi Sankyo Spain renews its corporate website.

Madrid, August of 2011- Daiichi Sankyo Spain debuts during these days the redesign of its website. The new page is intended to facilitate the user information of interest about the company, its initiatives and services in a simple and accessible. Daiichi Sankyo has an excellent track record of commitment to the advancement of medicine, with the improvement of the health and quality of life of millions of people around the world and we are proud to display it as dynamic and attractive through our new website ”, said immaculate Gil Rabadán, Director General of Daiichi Sankyo Spain.

History of passion and precision for medication

With the objective of showing the story of passion and precision by Daiichi Sankyo medications from 1899 in the web page is a complete tour of the history of the company in which stand out as important milestones such as the isolation of adrenaline by the first President of the companyJokichi Takamine, and the discovery of therapeutic classes as relevant in modern medicine as statins and the glitazonas, which have benefited millions of patients.

The website also emphasizes research and development (r & d) of the company, look in the Daiichi Sankyo excels because dedicated 20.1 per cent of its net sales to r & d, figures well above the industry average. This section details, for example, the projects of r & d currently being developed in cardiovascular and Oncology, areas in which has promising molecules are already in phase III development to treat diseases which persist a large number of medical needs to be filled as the problems of blood clotting or the SignetNCER’s lung, among others.

Despite the difficult international economic environment, Daiichi Sankyo is a company in full expansion and whose presence reaches about 60 countries around the world. In fiscal year 2010, Daiichi Sankyo rose 7.560 to 8.550 millions of euros net sales, results were made possible thanks to the efforts of about 30,500 employees of the company in all the world

information for health professionals and journalists

renewed website provides health professionals, after registration, information about their medicines marketed in Spain as well as other initiatives of interest among a calendar of conferences or a bibliographic search service.

The website also has a zone for media which includes the corporate and company press releases about their medications (previous record) and other information that may be useful for journalists as an image bank offices and centres of production and investigation of the company or biographies of its main leaders.

On Daiichi Sankyo

Daiichi Sankyo group is dedicated to the research and supply of innovative pharmaceutical products, both in mature markets as emerging, they face various medical needs of patients who are not yet covered. The company was created in 2005 through the merger of two companies of Japanese tradition and Daiichi Sankyo. Daiichi Sankyo is one of the 20 leading pharmaceutical companies in the world. In addition to the maintenance of its drugs for hypertension, Hyperlipidemia, and bacterial infections, the group is focused on the development of treatments for disorders thrombotic research in Oncology as well as new therapies in the cardiovascular area and metabolism. On the other hand, Daiichi Sankyo group has created a hybrid business model , which responds to the diversity of the market and customer seeking to optimize the opportunities for growth in the entire value chain.

The company’s global headquarters is in Tokyo. Its European base, Daiichi Sankyo Europe, is in Munich and has subsidiaries in 12 European countries as well as a plant of global manufacturing in Pfaffenhofen (Germany).